Trifluoroacetic acid → HCID 178522325, 화합물

HRID 1943445노트

반응식

HRID 1943445 반응식
[NH2:1][C@H:2]1[CH2:7][CH2:6][C@H:5]([NH:8][C:9]2[CH:10]=[C:11]([N:28]([CH:38]3[CH2:40][CH2:39]3)CC3C=CC(OC)=CC=3)[C:12]3[N:13]([C:15]([C:18]([NH:20][C:21]4[CH:26]=[CH:25][N:24]=[C:23]([F:27])[CH:22]=4)=[O:19])=[CH:16][N:17]=3)[N:14]=2)[CH2:4][CH2:3]1.CCN(C(C)C)C(C)C.Br[CH2:51][CH2:52][OH:53].C(O)(C(F)(F)F)=O>CC#N.CO>[CH:38]1([NH:28][C:11]2[C:12]3[N:13]([C:15]([C:18]([NH:20][C:21]4[CH:26]=[CH:25][N:24]=[C:23]([F:27])[CH:22]=4)=[O:19])=[CH:16][N:17]=3)[N:14]=[C:9]([NH:8][C@H:5]3[CH2:4][CH2:3][C@H:2]([NH:1][CH2:51][CH2:52][OH:53])[CH2:7][CH2:6]3)[CH:10]=2)[CH2:40][CH2:39]1

참가 물질

7

반응 조건

온도
60 °C

실험 절차

To a solution of 6-((trans)-4-aminocyclohexylamino)-8-(cyclopropyl(4-methoxybenzyl)amino)-N-(2-fluoropyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide (80 mg, 0.147 mmol) in MeCN (3 mL) was added DIEA (0.038 mL, 0.220 mmol) and 2-bromoethanol (36.7 mg, 0.294 mmol) and the reaction solution was stirred at 60° C. for 8 hrs. The reaction mixture was concentrated and treated with TFA (0.679 mL, 8.81 mmol) at 65° C. for 1 hr. The reaction mixture was diluted with MeOH and purified by HPLC (Phenomenex Axia Luna 5 micron 30×100 mm) 30% B (Solvent B=90% MeOH-10% H2O-0.1% TFA) to 100% B in A (Solvent A=10% MeOH-90% H2O-0.1% TFA) to isolate 8-(cyclopropylamino)-N-(2-fluoropyridin-4-yl)-6-((trans)-4-(2-hydroxyethylamino)cyclohexylamino)imidazo[1,2-b]pyridazine-3-carboxamide (19.9 mg, 0.042 mmol, 28.9% yield). LC/MS (BEH C18 2.1×50 mm 1.7u, Phenomenex Luna 5 micron C18 4.6×30 mm, 0 to 100 B in 2.2 min with 1 min hold time, Flow rate=2 mL/min, detection at 254 nm, Solvent A: 100% water/0.05% TFA; Solvent B: 100% ACN/0.05% TFA). Rt=0.65 (M+H=496.2). 1H NMR (400 MHz, MeOD) δ ppm 8.11-8.22 (1H, m), 8.04 (1H, s), 7.56-7.70 (1H, m), 7.21-7.40 (1H, m), 6.08 (1H, s), 3.66-3.89 (3H, m), 3.07-3.28 (3H, m), 2.50-2.69 (1H, m), 2.34-2.50 (2H, m), 2.20-2.35 (2H, m), 1.37-1.72 (4H, m), 0.78-0.99 (2H, m), 0.56-0.75 (2H, m) and 6-((trans)-4-(bis(2-hydroxyethyl)amino)cyclohexylamino)-8-(cyclopropylamino)-N-(2-fluoropyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide (18.7 mg, 0.036 mmol, 24.84% yield). LC/MS (BEH C18 2.1×50 mm 1.7u, Phenomenex Luna 5 micron C18 4.6×30 mm, 0 to 100 B in 2.2 min with 1 min hold time, Flow rate=2 mL/min, detection at 254 nm, Solvent A: 100% water/0.05% TFA; Solvent B: 100% ACN/0.05% TFA). Rt=0.65 (M+H=513.3). 1H NMR (500 MHz, DMSO-d6) δ ppm 11.38 (1H, s), 8.65-8.90 (1H, m), 8.22 (1H, d, J=5.50 Hz), 7.99 (1H, s), 7.60-7.71 (1H, m), 7.56 (2H, s), 6.82-7.14 (1H, m), 5.98 (1H, s), 3.78 (5H, t, J=5.50 Hz), 3.42-3.59 (1H, m), 3.14-3.36 (4H, m), 2.17-2.32 (2H, m), 1.98-2.17 (2H, m), 1.46-1.77 (2H, m), 1.18-1.44 (2H, m), 0.78 (2H, d, J=4.95 Hz), 0.63 (2H, d, J=2.75 Hz).

후처리

  1. concentrationThe reaction mixture was concentrated
  2. custompurified by HPLC (Phenomenex Axia Luna 5 micron 30×100 mm) 30% B (Solvent B=90% MeOH-10% H2O-0.1% TFA) to 100% B in A (Solvent A=10% MeOH-90% H2O-0.1% TFA)

출처 및 근거

ORD 기록
ord-8d310249e3f24b1d9cb8c91b47dce1a6
출처 데이터셋
uspto-grants-2013_03
특허 번호
US08389527B2

반응 노트

불러오는 중…